# SLYND
> **NDA211367** · New Drug Application · Sponsor: EXELTIS USA INC · Approved 2019-05-23
## Drug
- **FDA Application Number:** NDA211367
- **Application type:** New Drug Application
- **Brand name:** SLYND
- **Generic name:** DROSPIRENONE
- **Active ingredients:** DROSPIRENONE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** EXELTIS USA INC
- **Manufacturer:** Exeltis USA, Inc.
- **First approval:** 2019-05-23
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211367)
---
*AI Analytics · CC0 1.0*